» Articles » PMID: 28684784

Probing the Missing Mature β-cell Proteomic Landscape in Differentiating Patient IPSC-derived Cells

Overview
Journal Sci Rep
Specialty Science
Date 2017 Jul 8
PMID 28684784
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

MODY1 is a maturity-onset monogenic diabetes, caused by heterozygous mutations of the HNF4A gene. To date the cellular and molecular mechanisms leading to disease onset remain largely unknown. In this study, we demonstrate that insulin-positive cells can be generated in vitro from human induced pluripotent stem cells (hiPSCs) derived from patients carrying a non-sense HNF4A mutation, proving for the first time, that a human HNF4A mutation is neither blocking the expression of the insulin genes nor the development of insulin-producing cells in vitro. However, regardless of the mutation or diabetes status, these insulin-producing cells are immature, a common downfall off most current β-cell differentiation protocols. To further address the immature state of the cells, in vitro differentiated cells and adult human islets were compared by global proteomic analysis. We report the predicted upstream regulators and signalling pathways characterizing the proteome landscape of each entity. Subsequently, we focused on the molecular components absent or misregulated in the in vitro differentiated cells, to probe the components involved in the deficient in vitro maturation towards fully functional β-cells. This analysis identified the modulation of key developmental signalling pathways representing potential targets for improving the efficiency of the current differentiation protocols.

Citing Articles

Directed differentiation of pancreatic δ cells from human pluripotent stem cells.

Chen L, Wang N, Zhang T, Zhang F, Zhang W, Meng H Nat Commun. 2024; 15(1):6344.

PMID: 39068220 PMC: 11283558. DOI: 10.1038/s41467-024-50611-7.


Nanomedicine in the Treatment of Diabetes.

Andreadi A, Lodeserto P, Todaro F, Meloni M, Romano M, Minasi A Int J Mol Sci. 2024; 25(13).

PMID: 39000136 PMC: 11241380. DOI: 10.3390/ijms25137028.


Proteomics applications in next generation induced pluripotent stem cell models.

Manda V, Pavelka J, Lau E Expert Rev Proteomics. 2024; 21(4):217-228.

PMID: 38511670 PMC: 11065590. DOI: 10.1080/14789450.2024.2334033.


ECM-derived biomaterials for regulating tissue multicellularity and maturation.

Smandri A, Al-Masawa M, Hwei N, Fauzi M iScience. 2024; 27(3):109141.

PMID: 38405613 PMC: 10884934. DOI: 10.1016/j.isci.2024.109141.


Glucose Concentration in Regulating Induced Pluripotent Stem Cells Differentiation Toward Insulin-Producing Cells.

Wang C, Abadpour S, Olsen P, Wang D, Stokowiec J, Chera S Transpl Int. 2024; 37:11900.

PMID: 38304198 PMC: 10830798. DOI: 10.3389/ti.2024.11900.


References
1.
Hang Y, Stein R . MafA and MafB activity in pancreatic β cells. Trends Endocrinol Metab. 2011; 22(9):364-73. PMC: 3189696. DOI: 10.1016/j.tem.2011.05.003. View

2.
Vera E, Studer L . When rejuvenation is a problem: challenges of modeling late-onset neurodegenerative disease. Development. 2015; 142(18):3085-9. PMC: 6514401. DOI: 10.1242/dev.120667. View

3.
Magen I, Chesselet M . Genetic mouse models of Parkinson's disease The state of the art. Prog Brain Res. 2010; 184:53-87. DOI: 10.1016/S0079-6123(10)84004-X. View

4.
Rezania A, Bruin J, Arora P, Rubin A, Batushansky I, Asadi A . Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014; 32(11):1121-33. DOI: 10.1038/nbt.3033. View

5.
Paulo J, Gygi S . A comprehensive proteomic and phosphoproteomic analysis of yeast deletion mutants of 14-3-3 orthologs and associated effects of rapamycin. Proteomics. 2014; 15(2-3):474-86. PMC: 4511088. DOI: 10.1002/pmic.201400155. View